Telehealth Weight Loss/GLP-1 Prescribing: What PMHNPs Can Do in Texas

If you’re a psychiatrist or PMHNP watching the explosion of GLP-1 demand and wondering whether you can—or should—prescribe weight loss medications, you’re not alone. The short answer: Yes, psychiatrists can prescribe weight loss medications, including GLP-1 agonists like semaglutide (Wegovy/Ozempic), in all 50 states. PMHNPs can in most states, with varying collaboration requirements.

But the real question isn’t can you—it’s should you, and how do you do it correctly given the patchwork of state regulations, scope-of-practice concerns, and reimbursement realities?

Let’s cut through the noise. This guide walks through the clinical rationale, legal framework, state-specific rules, and economic realities of adding weight management to your psychiatric practice.

Why Psychiatrists Are Uniquely Positioned for Weight Management

Here’s the reality: many of your patients struggle with obesity, often directly caused or worsened by the medications you prescribe. Antipsychotics, mood stabilizers, some antidepressants—these can pack on 20-40 pounds or more. You’re already monitoring metabolic panels, glucose, and lipids. You’re already having conversations about lifestyle and self-image.

The rise of GLP-1 receptor agonists has blurred the line between metabolic and mental health treatment. These medications don’t just aid weight loss—emerging research suggests potential benefits for mood, impulse control, and substance use cravings. As Dr. Elliott Lewis (a psychiatrist board-certified in obesity medicine) argues: ‘If we truly understand that these systems are inseparable, then psychiatrists being involved in metabolic treatment makes complete sense.’

The clinical case for psychiatric involvement:

• Medication-induced weight gain is a leading cause of psychiatric medication discontinuation
• Obesity itself worsens depression, anxiety, and self-esteem
• GLP-1s show no increase in depression or suicidality (contrary to early fears)—in fact, clinical trials show slight improvements in depressive symptoms
• Psychiatrists already manage metabolic monitoring; adding weight management is a logical extension
• Patients benefit from integrated care rather than being bounced between specialists

The key is competency, not specialty title. Many psychiatrists are pursuing additional training in obesity medicine—some even obtaining board certification from the American Board of Obesity Medicine (ABOM), which is open to physicians of any specialty.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

The Legal Framework: Scope of Practice by Provider Type

Psychiatrists (MD/DO): Full Authority, With Caveats

As a licensed physician, you have broad prescriptive authority for FDA-approved medications. This includes:

• GLP-1 agonists (semaglutide/Wegovy, liraglutide/Saxenda, tirzepatide/Mounjaro)
• Controlled appetite suppressants like phentermine (Schedule IV)
• Other weight-loss medications (orlistat, naltrexone-bupropion, etc.)

No special certification is required to prescribe these medications. Your DEA registration and state medical license cover it.

However, scope of practice isn’t just about legal authority—it’s about competency. State medical boards expect physicians to practice within their training and expertise. If you start prescribing GLP-1s without understanding titration protocols, contraindications (like medullary thyroid cancer history), or management of side effects (nausea, gallbladder issues), you’re exposed to liability.

Best practices for psychiatrists:

• Complete CME in obesity medicine (60+ hours gets you ABOM eligibility)
• Collaborate or consult with endocrinology/primary care when appropriate
• Document the rationale clearly—especially when treating medication-induced weight gain
• Follow established protocols (FDA labeling, Endocrine Society guidelines)
• Stay within your comfort zone—refer complex metabolic cases

PMHNPs: State-Dependent Authority

Nurse practitioners face a more complex landscape. Your ability to prescribe weight-loss medications depends on:

1. Your state’s NP scope-of-practice laws (full practice, reduced practice, or restricted practice)
2. Whether you have a collaborating physician (required in ~26 states)
3. Your specialty training (are you practicing within psychiatric NP scope?)
4. Specific state rules about controlled substances and weight management

Full Practice Authority (FPA) States (~24 states + DC):NPs can evaluate, diagnose, and prescribe independently. Examples: Arizona, Colorado, Connecticut, Hawaii, Maryland, Montana, Nevada, New Hampshire, New Mexico, Oregon, Rhode Island, Washington, Wyoming, Alaska, Iowa, Idaho, Maine, Minnesota, Nebraska, North Dakota, South Dakota, Vermont, and DC.

In these states, a PMHNP can prescribe weight-loss medications without physician oversight—but consider:

• Some insurers still require physician involvement for high-cost GLP-1 authorizations
• Your state board expects you to practice within your competency (additional obesity training recommended)
• Pharmacies may question prescriptions outside typical psychiatric scope

Reduced/Restricted Practice States (collaboration required):In states like Texas, Florida, Pennsylvania, Alabama, NPs must operate under a physician collaboration or supervision agreement. This means:

• A written Prescriptive Authority Agreement (PAA) or protocol is required
• The collaborating physician must explicitly delegate authority for weight-loss medications
• Some states mandate chart reviews, monthly meetings, or ratios (e.g., Texas: 1 MD can supervise max 7 NPs)
• The physician’s name may appear on prescriptions (e.g., Pennsylvania)

Key state examples:

• Texas: PAA required, must specify drug categories. Monthly quality review meetings mandatory.
• Florida: NPs need physician protocol. ‘Autonomous’ NP status exists but excludes PMHNPs and doesn’t allow controlled substance prescribing for weight loss.
• New York: Collaboration required initially; after 3,600 hours, NPs can practice independently.
• Illinois: NPs with 4,000+ hours can obtain Full Practice Authority; less experienced NPs need collaboration agreements.
• California: Transitioning to independence via AB 890 (full implementation 2026), but Corporate Practice of Medicine rules still require physician involvement in clinic structure.

Bottom line for NPs: Check your state’s current requirements. In collaboration states, securing a physician partner who’s comfortable with weight management is essential—and adds cost.

State-Specific Prescribing Rules You Must Know

Beyond scope-of-practice laws, many states have specific regulations for prescribing weight-loss medications. Ignoring these can lead to board complaints, license discipline, or worse.

Florida: Strictest Obesity Prescribing Rules

Florida’s Board of Medicine has detailed regulations (Rule 64B15-14.004):

Requirements:

• BMI criteria: Patient must have BMI ≥30, or ≥25 with comorbidity
• Comprehensive evaluation: Document history, physical exam, labs to rule out secondary causes of obesity
• Informed consent: Written consent required, including risks/benefits
• Patient education: Provide state-mandated ‘Weight-Loss Consumer Bill of Rights’ brochure
• Follow-up: Face-to-face visits at least every 3 months for patients on obesity meds
• PDMP check: Required before each controlled substance prescription (E-FORCSE system)

Telehealth restriction: Florida law prohibits prescribing controlled substances via telehealth except for psychiatric treatment, inpatient/hospice care, or addiction treatment. Weight loss is not an exception—meaning you cannot prescribe phentermine via telehealth to Florida patients under current state law. (GLP-1s are non-controlled, so telehealth is permitted with proper evaluation.)

Enforcement: Florida has historically been aggressive about diet clinic compliance. Expect the possibility of board audits.

Texas: Collaboration Requirements

Texas doesn’t have obesity-specific rules as detailed as Florida’s, but:

• NPs must have written Prescriptive Authority Agreements
• Agreements must specify controlled substance prescribing authority
• Monthly quality assurance meetings between NP and collaborating physician
• PDMP checks required for controlled substances (though not mandated for all Schedule IV, it’s best practice)
• Telehealth permitted for weight-loss prescribing if standard of care met

New York: PMP Checks and Standard of Care

New York follows standard medical guidelines without obesity-specific state rules, but:

• I-STOP PMP check required before prescribing any Schedule II-IV controlled substance (including phentermine)
• Telehealth permitted and reimbursed at parity
• Experienced NPs (3,600+ hours) can practice independently

California: Corporate Practice Restrictions

California’s main barrier isn’t prescribing rules—it’s Corporate Practice of Medicine (CPOM):

• Only physicians can own medical practices or make clinical decisions at the entity level
• NPs (even those with AB 890 independence) must work within physician-owned structures or MSOs
• GLP-1s can be prescribed via telehealth
• Controlled substances require physician protocols for NPs until full AB 890 implementation

Pennsylvania: Collaboration and Prescription Requirements

• CRNPs need collaboration agreements to prescribe (no full FPA yet)
• Collaborating physician’s name must appear on prescriptions
• Standard of care applies; no specific obesity rules

Illinois: Emerging NP Independence

• Full Practice Authority available after 4,000 hours + education
• FPA-NPs can prescribe Schedule III-V independently; Schedule II requires consultation relationship for first year
• Medicaid reimburses NPs at 100% of physician rates (a financial plus)
• Telehealth parity established

Other Notable State Rules

• Mississippi: Banned off-label prescribing of GLP-1s for weight loss (must use FDA-approved obesity versions like Wegovy, not Ozempic)
• New Jersey: Requires comprehensive psychiatric screening before prescribing weight-loss meds, plus nutritional counseling
• Virginia: Mandates follow-up within 30 days of starting medication, then monthly initially
• Alabama: Requires in-person exam for controlled substance prescribing (no telehealth exception)

Telehealth Prescribing: Federal vs. State Rules

Here’s where it gets tricky: federal DEA waivers allow telehealth prescribing of controlled substances through December 31, 2025 (and likely beyond—extensions have been routine). This means federally, you can prescribe phentermine via telemedicine without a prior in-person exam.

But state law can override federal permission. Approximately 8 states have stricter rules:

States that effectively ban or severely restrict telehealth controlled substance prescribing:

• Florida (psychiatric exceptions only)
• Alabama (in-person exam required)
• South Carolina (strict telemedicine standards)
• Idaho (in-person for opioids and weight-loss controlled drugs)

In these states, you cannot prescribe phentermine remotely. You can prescribe GLP-1s (non-controlled) via telehealth if you meet standard-of-care requirements.

Best practices for telehealth weight management:

• Conduct live video consultation for initial evaluation (not just questionnaires)
• Document comprehensive history, current medications, vital signs (patient-reported or from recent in-person visit)
• Order appropriate labs (glucose, thyroid, lipids) before starting treatment
• Schedule regular follow-ups per state requirements (monthly to quarterly)
• Check state PDMP before prescribing controlled substances
• Use electronic informed consent documents
• Coordinate with patient’s primary care provider when possible

The Mississippi warning: In 2023, a physician’s license was suspended for prescribing Ozempic through instant messaging with no audio/video contact. The board deemed it failure to establish a proper patient relationship. Don’t cut corners.

Reimbursement: Can You Actually Get Paid?

The economics of weight management have shifted dramatically in the past two years.

Medication Coverage: The Game-Changer

Private Insurance:Most major insurers now cover GLP-1 medications for obesity (Wegovy, Saxenda, Mounjaro when approved for obesity), but with conditions:

• Prior authorization required (expect to document BMI, comorbidities, previous weight loss attempts)
• BMI thresholds (≥30, or ≥27 with comorbidity)
• Some plans impose 30-day supply limits initially (monitoring adherence)
• Phentermine typically covered with fewer restrictions (it’s much cheaper)

Medicare:As of November 2025, Medicare announced it will begin covering anti-obesity medications—a historic shift. Implementation details still emerging, but by 2026, Medicare Part D plans will include GLP-1s for eligible beneficiaries. This opens treatment to millions of seniors.

Medicaid:Coverage varies by state. Some state Medicaid programs already cover at least one GLP-1 for obesity; more will likely follow Medicare’s lead.

Visit Reimbursement

You bill standard E/M codes for medication management visits:

• Initial evaluation: 99204-99205 (new patient), or 90792 (psychiatric diagnostic evaluation) → ~$150-$250
• Follow-up visits: 99213-99214 (established patient, 15-30 minutes) → ~$75-$150
• Obesity counseling: G0447 (15 minutes behavioral counseling, BMI ≥30) → ~$25 (often used by PCPs/dietitians)

Reimbursement rates:

• Psychiatrists (MD/DO): 100% of physician fee schedule from Medicare and most insurers
• PMHNPs: 85% of physician rate from Medicare; varies by commercial payer (some pay 90-100%)
• Illinois exception: Illinois Medicaid pays APRNs 100% of physician rates

Telehealth parity:States with telehealth payment parity laws (California, New York, Illinois, Pennsylvania, others) require insurers to reimburse telehealth visits at the same rate as in-person. Medicare currently maintains parity for telehealth mental health visits through at least 2025.

Prior Authorization Reality

Expect PA requests for GLP-1s. You’ll need to document:

• BMI calculation with date
• Previous weight loss attempts (diet/exercise programs, prior medications)
• Comorbid conditions (diabetes, hypertension, sleep apnea, etc.)
• Treatment plan including lifestyle modifications

Some insurers require periodic re-authorization (every 6-12 months) with documented weight loss progress.

The Economics: Platform Model vs. DIY Marketing

Let’s talk about the elephant in the room: patient acquisition.

If you’re joining a telehealth platform like Klarity Health, patient acquisition is handled for you. The platform invests in marketing, matches pre-qualified patients to providers, and you pay per appointment (typically $X per new patient consultation). No upfront marketing spend, no wasted ad budget, no failed campaigns.

The alternative—building your own telehealth weight management practice—requires significant marketing investment:

DIY Marketing Costs (Realistic Estimates):

• Google Ads for weight loss keywords: $15-40+ per click (highly competitive). Most clicks don’t convert. Realistic cost per booked patient: $200-400+
• SEO investment: 6-12 months of consistent content, technical optimization, backlink building before meaningful results. Monthly cost: $1,500-3,000 with agency, or hundreds of hours of your time
• Directory listings: Psychology Today, Zocdoc charge monthly fees ($X0-X00) PLUS per-booking fees ($35-100+ for Zocdoc). You’re competing with hundreds of other providers on the same page
• Social media/content marketing: Time-intensive; takes months to build audience
• Total upfront risk: Many solo providers spend $3,000-5,000/month for 3-6 months before seeing ROI—if their marketing strategy works

Reality check: Acquiring a qualified psychiatric patient through DIY marketing typically costs $200-500+ when you factor in:

• Agency/consultant fees for campaign setup and management
• Ad spend testing and optimization (most campaigns fail initially)
• Staff time to handle leads and qualify them
• No-show rates from cold leads
• Months of SEO investment before results
• Cost of failed campaigns and pivots

The Klarity Health advantage:Instead of gambling $5,000/month on marketing channels, you pay only when a qualified patient books with you. The platform handles:

• Nationwide patient acquisition
• Pre-qualification (patients matched to your specialty and availability)
• Built-in telehealth infrastructure (no separate platform costs)
• Insurance credentialing and billing (for insured patients)
• Both insurance and cash-pay patient flow

For most providers—especially those starting out or scaling—this removes all acquisition risk. You control your schedule and only pay for actual appointments, not clicks that don’t convert or SEO experiments.

Clinical Protocols: How to Actually Do This Safely

If you decide to add weight management, here’s a practical framework:

Initial Evaluation

History:

• Obesity duration, previous weight loss attempts, family history
• Current medications (especially psychiatric meds causing weight gain)
• Medical history (thyroid disease, cardiovascular issues, gallbladder)
• Psychiatric screening (depression, binge eating disorder, body dysmorphia)
• Diet and exercise patterns

Physical:

• Height, weight, BMI calculation
• Blood pressure, heart rate
• Review of systems (GI symptoms, mood changes)

Labs:

• TSH (rule out hypothyroidism)
• Fasting glucose or HbA1c
• Lipid panel
• Liver function tests (baseline for GLP-1s)
• Pregnancy test if applicable

Assessment:

• Document BMI meets criteria (≥30 or ≥27 + comorbidity)
• Rule out contraindications (MEN2, personal history medullary thyroid cancer for GLP-1s; uncontrolled hypertension or CVD for phentermine)

Plan:

• Discuss medication options, mechanism of action, expected outcomes (5-15% weight loss typical)
• Set realistic goals (1-2 pounds per week)
• Provide lifestyle counseling (nutrition basics, exercise)
• Obtain informed consent

Medication Choices

GLP-1 Agonists (preferred for most patients):

• Semaglutide (Wegovy): 0.25mg weekly, titrate up to 2.4mg over 16-20 weeks
• Liraglutide (Saxenda): 0.6mg daily, titrate to 3.0mg over 5 weeks
• Tirzepatide (Mounjaro/Zepbound): Similar titration protocols

Pros: Significant weight loss (15-20% typical), cardiovascular benefits, no abuse potential, improving mood in some patientsCons: GI side effects (nausea, diarrhea common initially), cost (~$1,000-1,300/month without insurance), injection (some patients hesitate)

Phentermine (for short-term use):

• Start 15mg daily (or 37.5mg if tolerated)
• Typical course: 12 weeks (FDA approved for short-term use; some use longer off-label with monitoring)

Pros: Inexpensive (~$30-50/month), oral, rapid appetite suppressionCons: Stimulant (Schedule IV), tolerance develops, cardiovascular stimulation (avoid in HTN/CAD), insomnia/anxiety potential, limited long-term data

Other options: Naltrexone-bupropion (Contrave), orlistat (Xenical), topiramate off-label

Follow-Up Schedule

First month: Check-in at 2-4 weeks to assess tolerance, titrate dose, address side effects

Ongoing (state-dependent):

• Florida: Every 3 months minimum
• Virginia: Monthly for first few months
• Others: Every 1-3 months depending on medication and stability

Each visit:

• Weight, blood pressure
• Side effects check
• Review adherence
• Adjust dose as needed
• Reinforce lifestyle modifications
• PDMP check if prescribing controlled substance

When to Refer

• Patient has complex metabolic issues (uncontrolled diabetes, severe thyroid disease)
• Cardiovascular contraindications you’re not comfortable managing
• Surgical weight loss candidacy (BMI >40 or >35 with comorbidities)
• Eating disorder requiring specialized treatment

Addressing Common Concerns

‘Isn’t this outside my scope as a psychiatrist?’

Scope of practice is about competency, not specialty labels. You already:

• Monitor metabolic side effects of psychiatric medications
• Manage medication-induced weight gain
• Prescribe medications that affect multiple systems (e.g., SSRIs for GI issues off-label)
• Coordinate complex medical care

If you gain appropriate training in obesity medicine, prescribing weight-loss medications is a reasonable extension of comprehensive psychiatric care—especially for patients whose obesity is linked to their mental health or medication side effects.

Many psychiatrists are pursuing ABOM certification to solidify their credentials. But even without board certification, additional CME (20-40 hours focused on obesity pharmacotherapy) provides adequate foundation for straightforward cases.

‘What about the suicidality concerns with GLP-1s?’

The data is reassuring. A 2025 meta-analysis in JAMA Psychiatry found no increase in depression or suicidal ideation with GLP-1 medications versus placebo. Regulatory agencies (FDA and EMA) reviewed the early case reports and found no causal link.

In fact, clinical trials show GLP-1-treated patients had slightly lower rates of depressive symptoms compared to placebo. Potential mechanisms: weight loss improves self-esteem, reduced inflammation, possible direct CNS effects.

As a psychiatrist, you’re the ideal provider to monitor psychiatric side effects—you’re already doing this for every medication you prescribe.

‘Won’t endocrinologists or primary care push back?’

Collaboration, not competition. Frame it as:

• You’re addressing medication-induced weight gain in your psychiatric patients
• You’re providing integrated care rather than fragmenting treatment
• Many PCPs are overwhelmed and grateful for specialists managing this aspect

Communicate with the patient’s PCP. A simple note: ‘Patient is under my care for depression and has developed significant weight gain on mirtazapine. I’ve initiated Wegovy as part of integrated treatment. Please coordinate any metabolic monitoring. Happy to discuss.’

In reality, most PCPs have full panels and aren’t pursuing obesity medicine aggressively—there’s more demand than supply.

FAQs

Can psychiatrists prescribe Wegovy or Ozempic?Yes. Psychiatrists have full prescriptive authority for FDA-approved medications including GLP-1 agonists. Use Wegovy (FDA-approved for obesity) rather than off-label Ozempic for weight management to avoid regulatory issues (some states like Mississippi ban off-label GLP-1 use for weight loss).

Do PMHNPs need a collaborating physician to prescribe weight loss medications?Depends on your state. In full-practice-authority states (~24 states), no. In restricted/reduced practice states (Texas, Florida, Pennsylvania, Alabama, and ~22 others), yes—you need a written collaborative agreement explicitly authorizing weight-loss medication prescribing.

Can I prescribe weight loss medications via telehealth?Generally yes, but state rules vary. GLP-1s (non-controlled) can be prescribed via telehealth in all states if standard of care is met. Controlled substances like phentermine: allowed in most states under current federal waivers, but NOT in Florida (except for psychiatric treatment), Alabama, and a few others that require in-person exams. Check your state’s specific telehealth laws.

What are the reimbursement rates for weight management visits?Psychiatrists typically receive $100-$200 per follow-up visit (99213-99214 E/M codes) depending on complexity and payer. Medicare reimburses psychiatrists at 100% of physician fee schedule; NPs at 85% of physician rate (100% in Illinois Medicaid). Prior authorization required for GLP-1 medications but coverage is expanding rapidly.

How much training do I need to prescribe GLP-1s competently?Minimum: 10-20 hours of CME covering obesity pathophysiology, GLP-1 mechanism/side effects, titration protocols, and contraindications. Ideal: 60+ hours for ABOM board certification eligibility. Many medical education platforms offer obesity medicine certificates (e.g., Obesity Medicine Association CME courses).

What documentation do I need for compliance?

• Baseline: BMI calculation, informed consent, medical history, labs
• State-specific: Florida requires written informed consent, Consumer Bill of Rights, exam by MD/APRN, 3-month follow-ups; check PDMP for controlled substances
• Ongoing: Progress notes documenting weight, side effects, adherence, lifestyle counseling at each visit
• Prior auth: BMI, comorbidities, previous weight loss attempts, treatment plan

Which medication should I start with—GLP-1 or phentermine?GLP-1 agonists (semaglutide/Wegovy) are preferred for:

• Patients seeking long-term weight management
• Those with cardiovascular risk (GLP-1s have protective effects)
• Patients with diabetes or prediabetes
• Insurance coverage available

Phentermine is better for:

• Patients needing rapid appetite control
• Short-term boost (12 weeks typical)
• Cost-sensitive patients without insurance (much cheaper)
• Patients who prefer oral medication

Avoid phentermine in patients with: uncontrolled hypertension, cardiovascular disease, anxiety disorders (can worsen), history of stimulant abuse.

What about compounded semaglutide?Proceed with caution. FDA allows compounding only during drug shortages and with approved ingredients (semaglutide base, not sodium salt). Some states (Alabama, Mississippi) have cracked down on improper compounding. If using compounded GLP-1s:

• Verify pharmacy is 503B-registered outsourcing facility
• Ensure they use FDA-approved ingredients
• Document shortage status if questioned
• Consider brand name to avoid regulatory risk

What are the red flags that should stop me from prescribing?

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple endocrine neoplasia syndrome type 2 (MEN2)
• Pregnancy or breastfeeding
• History of pancreatitis (relative contraindication for GLP-1s)
• Active eating disorder (binge eating, anorexia, bulimia)—refer to specialized ED treatment first
• Unrealistic expectations (patient wants to lose 50 pounds in 2 months)
• Patient doctor-shopping (PDMP shows multiple controlled substance prescribers)

The Bottom Line

Can psychiatrists prescribe weight loss medication? Absolutely—and with the obesity epidemic, GLP-1 shortage turning into GLP-1 ubiquity, and the mental-metabolic health connection becoming clearer, many should consider adding it to their practice.

The keys to doing it right:

1. Get proper training (20-60 hours CME minimum)
2. Know your state’s rules (prescribing protocols, telehealth restrictions, NP collaboration requirements)
3. Follow clinical best practices (appropriate evaluation, monitoring, documentation)
4. Coordinate with other providers (PCP, endocrinology when needed)
5. Focus on patients where it makes sense (medication-induced weight gain, obesity with psychiatric comorbidity)

The economic reality: Weight management is a growing service line with improving reimbursement as insurers and Medicare expand coverage. But patient acquisition is expensive and time-consuming if you go it alone.

Platforms like Klarity Health solve the patient acquisition problem—pre-qualified patients, built-in infrastructure, pay-per-appointment model. No wasted ad spend, no months of SEO investment hoping for results, no gambling $5,000/month on marketing channels that may not work.

You control your schedule. You see patients who are already interested and matched to your specialty. You get paid for appointments, not clicks.

Whether you’re an established psychiatrist looking to expand services or a PMHNP starting your telehealth career, adding weight management—done correctly—is clinically sound, legally defensible, and increasingly profitable.

Ready to explore joining a telehealth platform that handles patient acquisition? Klarity Health connects psychiatrists and PMHNPs with patients seeking comprehensive mental health care, including medication management for weight concerns. Learn more about joining our provider network.

Sources and Citations

1. MedicalDirector Co., ‘How Much Does a Collaborative Physician Cost for Weight Loss, Telehealth, and Medspas? (2025 Definitive Guide)’ (2025) – Industry compliance guide analyzing NP scope and collaboration requirements
2. MedicalDirector Co., ‘Florida Weight Loss Clinic and Telehealth Compliance Guide (2025)’ (Updated 2025) – State-specific regulatory summary
3. MedicalDirector Co., ‘Texas Weight Loss Clinic & Telehealth Compliance Guide (2025)’ (Updated 2025) – Texas regulatory framework
4. Florida Administrative Code Rule 64B15-14.004, ‘Standards for Prescription of Obesity Drugs’ (Effective August 8, 2022, current through 2026) – Official Florida state regulation
5. Foley & Lardner LLP, ‘A Changing Regulatory and Reimbursement Landscape for Weight-Loss Drugs,’ Mondaq (July 24, 2023) – Legal analysis of state weight-loss regulations and enforcement actions
6. RxAgent (PharmD analysis), ‘Federal Permission, State Prohibition: The 2026 Telehealth Compliance Trap’ (December 16, 2025) – Analysis of federal-state telehealth controlled substance conflicts
7. Phillips, Susanne J., ’36th Annual APRN Legislative Update: Improving Access Through APRN Practice,’ The Nurse Practitioner Journal (January 2024) – Peer-reviewed state-by-state NP scope summary
8. Lewis, Elliott, MD, ‘Should Psychiatrists Prescribe GLP-1s? An Evidence-Based Perspective,’ DrLewis.com (January 4, 2026) – Psychiatrist analysis of scope and clinical rationale
9. Lewis, Elliott, MD, ‘GLP-1 Medications & Mental Health: Facts vs Myths,’ DrLewis.com (November 26, 2025) – Evidence review of psychiatric safety of GLP-1s
10. Axios Health News, ‘COVID-era telehealth prescribing extended again’ (November 18, 2024) – DEA/HHS waiver extension reporting
11. Axios, ‘Trump announces Medicare coverage of weight-loss drugs’ (November 6, 2025) – Medicare policy change announcement
12. TheraThink, ‘Insurance Reimbursement Rates for Psychiatrists [2026]’ (2026) – CPT code billing guide with current reimbursement data
13. Blue Cross Blue Shield of Texas, ‘Provider Notice: GLP-1 Obesity Supply Limit’ (October 4, 2024) – Insurer policy on supply limits
14. Cornell Law School Legal Information Institute, Florida Administrative Code Ann. R. 64B15-14.004 (accessed 2026) – Official regulatory text

This content is for informational purposes and does not constitute legal or medical advice. State laws change frequently; verify current requirements with your state medical/nursing board before prescribing. Prescribing decisions should be based on individual patient assessment and clinical judgment.

Source:

• https://www.medicaldirectorco.com/collaborative-physician-cost-weight-loss-telehealth/#:~:text=The%20answer%20is%20almost%20always,yes
• https://www.medicaldirectorco.com/collaborative-physician-cost-weight-loss-telehealth/#:~:text=Nurse%20Practitioners%20
• https://journals.lww.com/tnpj/fulltext/2024/01000/36thannualaprnlegislativeupdate__improving.6.aspx#:~:text=The%20Pennsylvania%20BON%20grants%20CRNPs%2C,more%20physicians%20to%20deliver%20healthcare
• https://journals.lww.com/tnpj/fulltext/2024/01000/36thannualaprnlegislativeupdate__improving.6.aspx#:~:text=The%20Illinois%20Department%20of%20Financial,collaborative%20agreement%20following%20a%20TTP
• https://rxagent.co/blog/telehealth-compliance-trap#:~:text=The%20DEA%20gave%20us%20the,evaluation%20at%20the%20federal%20level
• https://rxagent.co/blog/telehealth-compliance-trap#:~:text=Despite%20federal%20DEA%20waivers%20extending,traps%20for%20digital%20health%20providers
• https://rxagent.co/blog/telehealth-compliance-trap#:~:text=1.%20Florida%3A%20The%20%22No,for%20Stimulants
• https://www.mondaq.com/unitedstates/healthcare/1447512/a-changing-regulatory-and-reimbursement-landscape-for-weight-loss-drugs#:~:text=New%20Jersey%20law%20requires%20that,and%20identify%20the%20risks%20associated
• https://drlewis.com/glp-1-medications-psychiatry/#:~:text=You%20know%20these%20drugs,disorders%2C%20and%20possibly%20depression%20itself
• https://drlewis.com/glp-1-mental-health/#:~:text=Now%20let%E2%80%99s%20talk%20about%20potential,where%20things%20get%20really%20interesting